May. 11 at 4:20 PM
$BBIO news:
BridgeBio Pharma (Nasdaq: BBIO) reported new Phase 3 ATTRibute-CM data showing that acoramidis increased serum transthyretin (sTTR) early and significantly reduced intra-individual sTTR variability versus placebo, both linked to lower all-cause mortality. Acoramidis also cut outpatient worsening heart failure risk by 41% and reduced cardiovascular hospitalizations by 34% versus tafamidis in an indirect comparison.
The therapy consistently blunted NT-proBNP increases, preserved Kansas City Cardiomyopathy Questionnaire scores, and improved or maintained heart failure-related health status. Acoramidis, a near-complete (≥90%) TTR stabilizer, is approved as Attruby in the US and BEYONTTRA in multiple global markets for ATTR-CM.
https://www.stocktitan.net/news/BBIO/acoramidis-continues-to-demonstrate-disease-modifying-effects-in-bqwjm5liwwfy.html
